Patient-reported predictors of early treatment discontinuation: treatment-related symptoms and health-related quality of life among postmenopausal women with primary breast cancer randomized to anastrozole or exemestane on NCIC Clinical Trials Group (CCTG) MA.27 (E1Z03)

Wagner Lynne I.; Zhao Fengmin; Goss Paul E.; Chapman Judith-Anne W.; Shepherd Lois E.; Whelan Timothy J.; Mattar Bassam I.; Bufill Jose A.; Schultz William C.; LaFrancis Irving E.; Nagargoje Gauri G.; Vemuri Radhakrishna; Nikcevich Daniel A.; Sledge George W.; Cella David

首页> 外文期刊>Breast cancer research and treatment. >Patient-reported predictors of early treatment discontinuation: treatment-related symptoms and health-related quality of life among postmenopausal women with primary breast cancer randomized to anastrozole or exemestane on NCIC Clinical Trials Group (CCTG) MA.27 (E1Z03)

【24h】

Patient-reported predictors of early treatment discontinuation: treatment-related symptoms and health-related quality of life among postmenopausal women with primary breast cancer randomized to anastrozole or exemestane on NCIC Clinical Trials Group (CCTG) MA.27 (E1Z03)

机译：患者报告的早期治疗预测因素停止：治疗相关症状和与生物乳腺癌的后期妇女在NCIC临床试验组（CCTG）MA.27（E1Z03）上随机乳腺癌的绝经乳腺癌中患有原发性乳腺癌的生育健康生活质量。（CCTG）MA.27（E1Z03）

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Purpose Aromatase inhibitors are the most commonly prescribed adjuvant endocrine therapy for hormone-dependent early breast cancer in postmenopausal women. Among Canadian Cancer Trials Group MA.27 participants, anastrozole and exemestane had comparable 5-year event-free survival. This companion study examined differences in patient-reported treatment-related symptoms (TRS) and health-related quality of life (HRQL) among postmenopausal women randomized to anastrozole or exemestane.

机译：目的芳香酶抑制剂是绝经后妇女激素依赖性早期乳腺癌最常见的辅助内分泌治疗。在加拿大癌症试验组中，Anstrozole和Exemestane的参与者可比为期5年的无需生存。该伴侣研究检测了患者报告的治疗相关症状（TRS）和与患者患者随机的绝经后妇女与Anastrozole或Exemestans的患者有关的生命质量（HRQL）。

著录项

来源
《Breast cancer research and treatment.》 |2018年第3期|共12页
作者
Wagner Lynne I.; Zhao Fengmin; Goss Paul E.; Chapman Judith-Anne W.; Shepherd Lois E.; Whelan Timothy J.; Mattar Bassam I.; Bufill Jose A.; Schultz William C.; LaFrancis Irving E.; Nagargoje Gauri G.; Vemuri Radhakrishna; Nikcevich Daniel A.; Sledge George W.; Cella David;
展开▼
作者单位

Wake Forest Sch Med Dept Social Sci &

Hlth Policy Med Ctr Blvd Winston Salem NC 27151 USA;

Dana Farber Canc Inst Boston MA 02115 USA;

Harvard Med Sch Massachusetts Gen Hosp Boston MA USA;

CCTG Kingston ON Canada;

CCTG Kingston ON Canada;

CCTG Kingston ON Canada;

Wichita NCORP Wichita KS USA;

Michiana Hematol Oncol PC Mishawaka IN USA;

Swedish Amer Reg Canc Ctr Rockford IL USA;

Mercy Hosp Joplin Joplin MO USA;

Mercy Hosp Coon Rapids MN USA;

West Michigan Canc Ctr Kalamazoo MI USA;

Essentia Hlth Canc Ctr Duluth MN USA;

Stanford Univ Stanford CA USA;

Northwestern Univ Chicago IL USA;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类肿瘤学;
关键词
Quality of life; Treatment-related symptoms; Patient-reported outcomes; Endocrine therapy adherence; Tolerability;

机译：生活质量;治疗相关的症状;患者报告的结果;内分泌治疗依从性;可耐受性;

相似文献

外文文献
专利

1. Patient-reported predictors of early treatment discontinuation: treatment-related symptoms and health-related quality of life among postmenopausal women with primary breast cancer randomized to anastrozole or exemestane on NCIC Clinical Trials Group (CCTG) MA.27 (E1Z03) [J] . Wagner Lynne I., Zhao Fengmin, Goss Paul E., Breast cancer research and treatment. . 2018,第3期

机译：患者报告的早期治疗预测因素停止：治疗相关症状和与生物乳腺癌的后期妇女在NCIC临床试验组（CCTG）MA.27（E1Z03）上随机乳腺癌的绝经乳腺癌中患有原发性乳腺癌的生育健康生活质量。（CCTG）MA.27（E1Z03）
2. Outcomes in women with invasive ductal or invasive lobular early stage breast cancer treated with anastrozole or exemestane in CCTG (NCIC CTG) MA.27 [J] . Strasser-Weippl K., Sudan G., Ramjeesingh R., European journal of cancer: official journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR) . 2018,第期

机译：患有侵入性导管或侵入式小叶早期乳腺癌的女性的结果，CCTG（NCIC CTG）MA27中的Astrozole或Exemestane治疗
3. First results of a randomized phase III trial comparing exemestane versus tamoxifen as first-line hormone therapy (HT) for postmenopausal women with metastatic breast cancer (MBC) — EORTC 10951 in collaboration with the exemestane working group and NCIC Clinical Trials Group [J] . R.Paridaens, P.Therasse, L.Dirix, European Journal of Cancer Supplements . 2004,第3期

机译：一项随机III期试验的初步结果，该试验比较了依西美坦与他莫昔芬作为绝经后转移性乳腺癌（MBC）一线激素疗法（HT）的一线激素治疗— EORTC 10951与依西美坦工作组和NCIC临床试验组合作
4. Analysis of health-related quality of life data from cancer clinical trials based on the item response theory. [D] . Wang, Miao. 2006

机译：基于项目响应理论的癌症临床试验中与健康相关的生活质量数据分析。
5. Patient-reported predictors of early treatment discontinuation: Treatment-related symptoms and health-related quality of life among postmenopausal women with primary breast cancer randomized to anastrozole or exemestane on NCIC Clinical Trials Group (CCTG) MA.27 (E1Z03) [O] . Lynne I. Wagner, Fengmin Zhao, Paul E. Goss, -1

机译：患者报告的早期治疗中断的预测因素：NCIC临床试验组（CCTG）MA.27（E1Z03）中将绝经后原发性乳腺癌患者随机分配给阿那曲唑或依西美坦治疗的症状和健康相关的生活质量
6. Exemestane Versus Anastrozole in Postmenopausal Women With Early Breast Cancer: NCIC CTG MA.27—A Randomized Controlled Phase III Trial [O] . Goss, Paul E., Ingle, James N., Pritchard, Kathleen I., 2013

机译：绝经后早期乳腺癌妇女的依西美坦与阿那曲唑比较：NCIC CTG MA.27－一项随机对照的III期临床试验

Patient-reported predictors of early treatment discontinuation: treatment-related symptoms and health-related quality of life among postmenopausal women with primary breast cancer randomized to anastrozole or exemestane on NCIC Clinical Trials Group (CCTG) MA.27 (E1Z03)

摘要

著录项

相似文献

相关主题

期刊订阅